Abstract
Introduction
The staggering diversity in human genomes is exemplified by the numerous unique in addition to the many common genetic features and phenotypes present in each individual. Genotype-phenotype associations promise to reveal the basis of many human attributesboth beneficial and deleterious.
1 This is truthful, despite the hubris of genetic essentialism: the belief that genes are deterministic of all phenotypes. 2, 3 The popular concept that biological knowledge is the product of independent research by an investigator working in isolation is no longer unrivaled. In other fields of research, most notably particle physics, the concept is endangered, and almost extinct. There is a growing consensus that the sum of the efforts of a community of investigators working together is much greater than that of the parts in isolation. 4, 5 This was noted several millennia ago by King Solomon the Wise. 7 Within biomedical science, human genome analysis has been the forerunner of data sharing and community analysis by virtue of the digital nature of genetic data, which facilitates standardization, compilation, searching, and computation. 1 This has been accelerated by massively parallel next generation sequencing and analysis (NGSA) and systematized funding by the National Institutes of Health. 36, 37 Concomitant compilations or searchable, standardized phenotype descriptions, unfortunately, have lagged far behind genome compilation. The vast majority of human genome and exome sequences are associated either with no phenotypic information or a single bivariable. Efforts are underway to standardize phenotype collections, 7, 8 but as yet have not been married with NGSA. 33 The Journal of Genomes and Exomes is a new forum for structured reporting of rich phenotypic data together with corresponding comprehensive sets of variants culled from high quality NGSA of genomes, exomes, and gene panels. 9 Here we describe the rationale for a working model of the initial standardized data formats and minimal descriptors of human genome sequences and phenotypes for the Journal as well as provide examples.
Results
The primary goal of standardized reporting of genome-scale variation and attendant phenotypes is to allow comparisons to be made seamlessly between studies. In this way, the Journal will facilitate testing of the significance of genotype-phenotype associations, particularly those in rare genetic diseases. The requirements for cancer genomics are somewhat different and are in development. To achieve the goal of cross study comparisons, data formats should be simple, searchable and in common use in order to allow compilation. Flat files of delimited (eg, comma or tab separated) values are preferred. Another prerequisite for data formats is future interoperability with additional layers of genomic complexity (such as haplotypes) and phenotypic complexity (such as quantitative phenotypic descriptions). All datasets must, of course, be de-identified in compliance with the Health Information Privacy Act (HIPAA).
10 The determination of an institutional review board (IRB) regarding whether such datasets constitute research involving human subjects or ought to be waived should be noted. If the former, a statement indicating that the study was approved by an IRB, that informed consent was obtained from all subjects, and that all research was done in accordance with the Declaration of Helsinki, must be included.
nGsA Metrics
Deep NGSA is an accurate and sensitive tool to identify and genotype most nucleotide variants at genome scale. NGSA on an Illumina HiSeq 2000 sequencer with an average of 36X and 60X aligned coverage of 100 base pairs (bp) accurately reads genotypes ∼95% and ∼97%, respectively, of the 3,101,788,170 nucleotide reference genome (the "callable" genome). 13 This was recently recapitulated with 2 × 100 nucleotide HiSeq 2500 NGSA.
11 100 gigabases (GB) of aligned sequence (average 32X) is becoming a standard for new, reportable genotypes in short read genomes with most NGSA technologies. 13 Standardized metrics for sequence depth for exomes are less well established. With singleton 100 nuceotide HiSeq 2000 sequencing of Illumina hybrid selection-enriched exomes (approximately 62 Mb of targets), approximately 2% of target nucleotides have no coverage (C0, Fig. 1A ). This proportion does not change in the range of 5-20 GB of aligned sequences (Fig. 1A) . Fortunately, C0 nucleotides in exome NGSA are highly reproducible, 12 defining a "callable" exome. 13 The proportion of exome nucleotides with 16X coverage (C16), a conservative depth for highly accurate genotyping, 12 increases somewhat linearly over the same range of aligned sequence (Fig. 1B) . Also using these methods, 8 GB of aligned exome sequence corresponds to approximately 70X average coverage and C16 for approximately 99% of target nucleotides (Fig. 1B) . Exome capture enrichment is available from multiple vendors and in multiple versions, all covering slightly different targets. Numerous studies have compared depth of coverage and percent of targeted nucleotides covered across exome enrichment from different companies and highlight that each lab may produce may produce different results even with the same enrichment technology. [22] [23] [24] Consequently, rather than recommend a specific amount of sequence required for each exome enrichment version, we suggest a minimum average coverage of 70X for targeted regions and C16 for each variant called. The percent of targeted nucleotides covered at C16 and C0 should be reported. Some laboratories apply different coverage minimums for homozygous and heterozygous variants, albeit tools such as GATK do not apply simple coverage filters for calling genotypes, and parameterization is not yet being standardized between centers.
Standardized metrics for sequence depth for gene panels are relatively primitive. The depth of NGSA coverage for accurate and sensitive genotyping of a panel comprising 437 recessive disease genes and 1,978,041 nucleotides enriched by hybrid selection has been extensively evaluated. 12 Agilent hybrid enrichment of these targets, followed by singleton 50 nucleotide Illumina GAIIx or HiSeq 2000 NGSA to aligned sequence depth of 0.75-2.00 GB, gave a highly reproducible subset representing approximately 1% of target nucleotide with C0. 12 The proportion of target nucleotides with 20X coverage (C20) increased linearly over the same range of aligned sequence. 12 1 GB of sequence corresponded to C20 for approximately 90% of target nucleotide and ∼250X average coverage. More recently, we have evaluated the same metrics for a panel comprising 526 recessive disease genes and 2,158,661 nucleotides (Dinwiddie et al, unpublished). Illumina hybrid enrichment of these targets, followed by singleton 100 nucleotide Illumina HiSeq 2000 NGSA to an aligned sequence depth of approximately 3 GB, gave 0.48% of highly reproducible target nucleotide with C0. 3 GB of sequence corresponded to an average coverage of 850X and to C16 for approximately 98.5% of target nucleotide. 1 GB (or ∼350X coverage) is suggested as the interim minimum standard for reportable hybrid selectionenriched panels. Enrichment of targeted panels for NGSA using multiplexed polymerase reaction should theoretically yield only cognate amplicons, 12 but the same interim minimum standard for reporting is desired. Coverage recommendations are much more difficult to standardize in targeted oncology panels, since tumor cell populations can be oligoclonal or polyclonal, differing in somatic mutations. 25 NGSA technologies are evolving very rapidly. Current technologies and protocols result in different read lengths, raw sequence accuracies, and phasing errors. It is therefore important to record the methods with sufficient detail to allow a future understanding of whether discrepancies between studies were the result of methodological differences. A minimum set of NGSA methodological data fields are the sample preparation (library generation) vendor and version, enrichment technology vendor and type (hybrid enrichment or amplicons), sequencing technology vendor and type (panel, exome, genome), and sequence type (singleton or paired, read length). Average sequence quality scores, alignment algorithm, and parameterization are becoming less material as NGSA technologies mature, but are desired.
scope of Variant Reporting
100 GB raw genome sequences and 3.1 GB consensus human genome sequences (or 8 GB raw exome sequences and 62 Mb consensus exome sequences) are unwieldy. Provided that the version of the human reference used for alignment is noted, there is little rationale at present for retention of reference nucleotides in most compilations of human genome sequences. Currently, NGSA cannot reliably assemble haplotypes over meaningful genomic intervals at genome scale. When possible, however, retention of phase information will become very important. At present, NGSA is limited in its ability to detect copy number variations (CNV) or structural variations. Thus, the initial minimal descriptors of human genome sequences for the Journal will be nucleotide and polynucleotide substitutions, insertions, and deletions. The cutoff for the size of callable polynucleotide variants will vary for substitutions, insertions, and deletions as well as among NGSA technologies. Typically, in our experience, contiguous substitutions within a read are limited to a maximum size of about five nucleotides, insertions to about fifty nucleotides and deletions to about two kilobases (Dinwiddie et al, unpublished). However, this is highly dependent on the alignment and variant detection methods used. In the future, additional variant categories will be added, as methods are validated for their identification by NGSA, genotyping and imputation of pathogenicity (such as CNV, chromosomal events, regulatory variants, synonymous variants of phenotypic relevance). however, allele frequencies from other populations are welcomed. This is particularly important since many variants annotated as causative of uncommon monogenic diseases have allele frequencies that are too high to be causative. Allele frequency .1% and homozygosity in healthy individuals useful for distinguishing variants annotated as causative of uncommon monogenic diseases from misannotated common polymorphisms. 21 Known exceptions exist including Factor V Leiden (frequency 3%-8% in general US and European populations), Hemoglobin S and C (7.4% and 1.8% in African Americans, respectively) and hemochromatosis HFE p.C282Y (11% in European populations); A standardized data format that combines these elements is shown in Table 2 , where individual variations are rows and descriptors as columns. The magnitude of variant reporting of this type is shown in Table 3 . Genome, exome and targeted gene panel NGSA at depths of 120 GB, 8 GB and 3 GB, respectively, yield, on average, 4,079,138, 87,542 and 8,510 variants, respectively. Since files with 4 million rows are not trivial to search, we suggest reporting only of gene-associated variants, or variants that may have a functional consequence (ACMG Categories 1-3, thus omitting most synonymous and intronic variants). For causative variants other than nucleotide substitutions in reports of genetic diseases, confirmatory studies in trios are requested using established, traditional methods.
Variant Annotation standardization

phenotypic Description and standardization
Rich description of the components of phenotypes is necessary for meta-analysis of genotype-phenotype associations. Standardized Human Phenotype Ontology (HPO) or SNOMED CT (Systematized Nomenclature of Medicine) terms are becoming the consensus for this purpose. 7, 8, 27, 28 Most SNOMED CT terms are qualitative clinical findings derived from human diseases. They have limitations for summary of phenotype (OMIM), and primary causative locus (HGNC). In the future it will be desirable to add modifiers to the terms, such as age of onset, frequency, severity, duration, complications, and outcomes. It will also be very important to add treatments and responses to treatments. It is envisaged that these innovations will be added in time.
Discussion
Genomic medicine is a new, structured approach to disease discovery, diagnosis, and management that prominently features NGSA. 4 Over the next several years, genomic medicine is anticipated to discover the genes that underpin ∼3500 Mendelian disorders of unknown cause. It will also identify genotypephenotype relationships and on an unparalleled scale. In addition, it promises to deliver simultaneous, comprehensive differential diagnostic testing of likely genetic illnesses at time of presentation, accelerating molecular diagnosis, increasing rates of ascertainment, minimizing duration of empiric treatment, and time-to-genetic counseling. In the longer term, genomic medicine will help pharmacogenetically-informed treatment regimens to be implemented. [5] [6] [7] Lastly, it will increasingly provide molecular diagnoses and potential drug/ dosing selections that could not have been ascertained by conventional approaches by virtue of pleiotropic clinical presentation and genetic heterogeneity. [8] [9] [10] [11] This is anticipated to transform the diagnosis and treatment of genetic diseases from phenotypedriven, and genotype-assisted, to genotype-driven and phenotype-assisted. 12 The imminence of genomic medicine has been substantially hastened by inexpensive sequencing of exomes (all protein coding exons) and targeted gene panels. 5, 6, 8, 10, 17, [20] [21] [22] Exomes are about ten-fold less costly than whole genomes. Targeted gene panels, in turn, are less costly than whole exomes. In addition, their interpretation and, thus, actionability are much simpler. Besides the discovery and clinical testing of genetic disease and pharmacoligically relevant genes, these technologies are also expanding the applicability of sequence analysis. Examples include oligogenotype-phenotype relationships, such as epistasis, and ascertainment of the breadth of clinical and genetic heterogeneity in diseases.
The Journal of Genomes and Exomes seeks to assist in the implementation of genomic medicine by scalable reporting of high quality genome, exome, and gene panel sequences with attendant, detailed phenotypes. Through such reports, the Journal seeks to be an international forum for community-based confirmation or rebuttal of preliminary genotypephenotype relationships by requiring the submission of supplementary, structured information in a flat file format. Herein we have described the initial structured templates for submission of such information, the rationale for these templates and examples. The Journal of Genomes and Exomes is keen to receive feedback regarding these structured templates and examples. This is intended to be a responsive community resource. The greater the number of high quality exomes and genomes we publish, the more valuable this resource for discoveries and refinements in genomic medicine will be.
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